You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. HBI-002 to Treat Diabetic Retinopathy

    SBC: Hillhurst Biopharmaceuticals, Inc.            Topic: NEI

    PROJECT SUMMARY Diabetic retinopathy (DR) is a neurovascular complication of diabetes mellitus and the leading cause of blindness in working age adults and elderly, affecting approximately 4.2 million diabetes patients in the US, of which 655,000 have vision-threatening DR. There is an urgent need for the development of additional approaches to prevent and treat diabetic retinopathy, as the curren ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  2. Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NHLBI

    Despite prevalent use of anti-platelet and anti-lipid therapies, stroke remains the third major cause of death and is the leading cause of adult disability in the US with an estimated cost in the range of $34 billion annually. Approximately 20% of the annual 795,000 stroke patients die within one year and 15-30% are permanently disabled. Antiplatelet therapy is mainly used for primary prevention o ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  3. A novel approach to restricting the spread of neurofibrillary tau

    SBC: NOVORON BIOSCIENCE INC            Topic: NIA

    7. Project Summary Alzheimer’s disease (AD) is the most common cause of dementia and is a growing problem as populations age. More than 25 million people are affected by dementia worldwide with most suffering from AD. AD is characterized by the presence of plaques of insoluble amyloid-beta (Aβ) and tangles of hyperphosphorylated aggregates of the cytoskeletal protein, tau. Thus far, most AD tre ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Small Molecule Antagonists of PAR-2 for treatment of asthma

    SBC: PARMEDICS, INC            Topic: NHLBI

    ABSTRACT: Current treatments for asthma largely are aimed at reducing exacerbations by directly treating airway inflammation. While successful in a subset of patients, asthma exacerbations remain a significant cause of morbidity and mortality and can result in airway injury, lung function decline and death. Exacerbations in more severe asthmatics are of particular concern, as health care costs and ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  5. Using Rendever to improve the quality of life of older adults with cognitive impairments in senior living communities and their family members who live at a distance.

    SBC: RENDEVER, INC.            Topic: NIA

    ABSTRACTThe United States is experiencing a public health crisis on a massive scale due to the number of people with dementia, lack of cures, and challenges associated with caregiving for this population.1,2 until cures for the dementias are discovered, new technologies and interventions are imperative that can reduce the stress and emotional burden of Alzheimer’s disease (AD) and Alzheimer’s ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  6. Multi-modal cloud based system for detecting early signs of driver cognitive decline and/or high risk driving behaviors

    SBC: PHYSICAL SCIENCES INC.            Topic: NIA

    Project Summary/AbstractPhysical Sciences Inc. (PSI), in collaboration with Michigan State University (MSU) and the University of Michigan (U-M), proposes to develop a novel technology that will non-intrusively monitor driver cognitive decline and/or high-risk driving behavior that is especially suited for seniors (aged andgt;65). Contextual physiological biomarkers along with computer vision base ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  7. An automated system to interpret echocardiography to predict adverse outcomes in patients with right ventricular dysfunction in daily hospital practice

    SBC: MPROBE, INC.            Topic: NHLBI

    Project Summary Right ventricle (RV) dysfunction is a common and complex form of pediatric heart disease. It is also a common contributor to morbidity and mortality for patients with congenital heart diseases (CHD). Due to the complex geometry of the RV and its relative adaptability to changing physiologic conditions, RV dysfunction is poorly understood and difficult to characterize precisely and ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  8. A therapeutic for Lyme disease based on Peptidoglycan Recognition Protein 1

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    ABSTRACTLyme disease, the most common vector-borne illness in North America, is caused by the spirochete B. burgdorferi. Infection begins in the skin following an infected tick-bite and acute illness is characterized by headache, fever and myalgia. Currently, there is no human vaccine against Lyme disease and therapeutic administration of antibiotics remains the recommended treatment option. In th ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  9. MiGo: wearable sensors that combine actionable data with a behavioral intervention to improve function after stroke

    SBC: FLINT REHABILITATION DEVICES, LLC            Topic: NICHD

    One of the most impenetrable problems challenging full recovery after stroke is the gap between motor capacity that a stroke survivor regains (i.e. what they can do) and how they engage in home and community activities (i.e. what they choose to do). To address this challenge, Flint Rehab developed MiGo, a novel multi-sensor activity tracker specifically designed for stroke survivors. The unique fe ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  10. CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma

    SBC: ROCK IMMUNE LLC            Topic: 102

    Abstract Cutaneous T-cell lymphoma (CTCL) is a type of extra-nodal non-Hodgkin’s lymphoma characterized by skin lesions resulting from infiltration of malignant T lymphocytes. Mycosis fungoides and Sezary syndrome are the two most common types of CTCL. Although treatments exist, they are mainly palliative with low response and durability of response without any cure. The objective response rate ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government